SAb Biotherapeutics logo
  • Overview
    • Corporate Video
    • Executive Management
    • Board of Directors
    • Board Committees
    • Corporate Governance
    • Scientific Advisory Board
  • Platform
    • Platform Overview
    • Publications
  • Pipeline
    • Pipeline Overview
    • SAB-195: CDI
    • SAB-176: Influenza
  • Partnering
  • Patients
    • C. diff Patient Information
    • Influenza
  • Media
    • News & Press Releases
    • Events
    • Presentations
    • Publications
  • Shareholder Services
    • Overview
    • SEC Filings
    • Stock Quote & Chart
    • Corporate Governance
    • Board Committees
    • Analyst Coverage
    • RSS Feeds
    • Contact Us
  • Overview
    • Corporate Video
    • Executive Management
    • Board of Directors
    • Board Committees
    • Corporate Governance
    • Scientific Advisory Board
  • Platform
    • Platform Overview
    • Publications
  • Pipeline
    • Pipeline Overview
    • SAB-195: CDI
    • SAB-176: Influenza
  • Partnering
  • Patients
    • C. diff Patient Information
    • Influenza
  • Media
    • News & Press Releases
    • Events
    • Presentations
    • Publications
  • Shareholder Services
    • Overview
    • SEC Filings
    • Stock Quote & Chart
    • Corporate Governance
    • Board Committees
    • Analyst Coverage
    • RSS Feeds
    • Contact Us
Home > News > Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
http://Introduction%20to%20SAB’s%20Unique%20DiversitAb™%20Immunotherapy%20Platform
October 13, 2021

Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform

Share

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

September 28, 2021
SAb Biotherapeutics logo
  • ©2023 SAb Biotherapeutics, Inc.
  • All Rights Reserved
  • Terms & Conditions
  • Privacy Policy
  • Conflict of Interest Policy
  • Contact